Research Article
Mother-to-Child Transmission of HIV Infection and Its Determinants among Exposed Infants on Care and Follow-Up in Dire Dawa City, Eastern Ethiopia
Table 1
Sociodemographic and clinical characteristics of HIV-exposed infants on follow-up care in Dire Dawa, Ethiopia, September 2014.
| Variables | Total, (%) | Negative, (%) | Positive, (%) |
| Sex of infant | | | | Male | 189 (49.5%) | 163 (86.2%) | 26 (13.8%) | Female | 193 (50.5%) | 159 (82.4%) | 34 (17.6%) | Infant age at enrollment | | | | ≤6 weeks | 319 (83.5%) | 275 (86.2%) | 44 (13.8%) | >6 weeks | 63 (16.5%) | 47 (74.6%) | 16 (25.4%) | Residence | | | | Urban | 341 (89.3%) | 296 (86.8%) | 45 (13.2%) | Rural | 41 (10.7%) | 26 (63.4%) | 15 (36.6%) | Place of delivery | | | | Health institution | 344 (90.1%) | 303 (88.1%) | 41 (11.9%) | Home | 38 (9.9%) | 19 (50.0%) | 19 (50.0%) | PMTCT intervention | | | | On ART | 100 (26.2%) | 94 (94.0%) | 6 (6.0%) | PMTCT | 153 (40.0%) | 133 (86.9%) | 20 (13.1%) | None | 129 (33.8%) | 95 (73.6%) | 34 (26.4%) | PMTCT regimen | | | | Already on HAART | 100 (26.2%) | 94 (94.0%) | 6 (6.0%) | None | 129 (33.8%) | 95 (73.6%) | 34 (26.4%) | sdNVP | 91 (23.8%) | 78 (85.7%) | 13 (14.3%) | sdNVP + AZT + 3TC | 55 (14.4%) | 48 (87.3%) | 7 (12.7%) | sdNVP + AZT for 4 weeks | 7 (1.8%) | 7 (100.0%) | 0 (0.0%) | ARV prophylaxis at birth | | | | Yes | 298 (78.0%) | 276 (92.6%) | 22 (7.4%) | No | 84 (22.0%) | 46 (54.8%) | 38 (45.2%) | Infant ARV regimen | | | | None | 84 (22.0%) | 46 (54.8%) | 38 (45.2%) | sdNVP | 127 (33.2%) | 114 (89.8%) | 13 (10.2%) | sdNVP + AZT 4 wks | 36 (9.4%) | 34 (94.4%) | 2 (5.6%) | AZT + sdNVP + 3TC | 104 (27.2%) | 98 (94.2%) | 6 (5.8%) | Others | 31 (8.1%) | 30 (96.8%) | 1 (3.2%) | Feeding practice | | | | ERF | 80 (20.9%) | 78 (97.5%) | 2 (2.5%) | EBF | 267 (69.9%) | 233 (87.3%) | 34 (12.7%) | MF | 35 (9.2%) | 11 (31.4%) | 24 (68.6%) | Growth pattern | | | | Normal | 342 (89.5%) | 291 (85.1%) | 51 (14.9%) | Growth failure | 40 (10.5%) | 31 (77.5%) | 9 (22.5%) |
|
|
AZT, zidovudine; sdNVP, single dose nevirapine; 3TC, lamivudine.
|